{"nctId":"NCT00458302","briefTitle":"Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir","startDateStruct":{"date":"2007-06"},"conditions":["HIV Infections","AIDS Virus","Human Immunodeficiency Virus","Acquired Immunodeficiency Syndrome Virus"],"count":256,"armGroups":[{"label":"darunavir monotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: darunavir (DRV, TMC114)"]},{"label":"darunavir + 2 NRTI","type":"EXPERIMENTAL","interventionNames":["Drug: darunavir (DRV, TMC114)"]}],"interventions":[{"name":"darunavir (DRV, TMC114)","otherNames":[]},{"name":"darunavir (DRV, TMC114)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with documented HIV-1 infection\n* Patients currently receiving HAART for at least 24 weeks\n* Plasma viral load \\< 50 copies/mL for at least 24 weeks prior to screening (two results must be documented)\n* Patients taking the same antiretroviral combination for at least 8 weeks before screening\n* Patients and physician's preference to change the current HAART regimen for reasons of simplification and/or toxicity\n* CD4 \\> 100/mm3 at the start of HAART and \\> 200/mm3 at screening.\n\nExclusion Criteria:\n\n* No history of virological failure defined as two consecutive plasma HIV-1 RNA \\> 500 copies/mL while on previous or current antiretroviral therapy\n* No history of any primary PI mutations as defined by the IAS-USA guidelines 2006\n* No patients co-infected with hepatitis B\n* No pregnant or breastfeeding women\n* No active clinically significant disease or life threatening disease or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Virological Response [Per Protocol (PP) - Time to Loss of Virologic Response (TLOVR), < 50 Copies/ml, Week 48]","description":"Virological response is defined as the number of patients in the PP population with a plasma viral load \\< 50 HIV RNA copies/ml at Week 48. Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR). In addition, any switch in background nucleoside reverse transcriptase inhibitors (NRTIs) equaled failure\\* (referred to as a Switch Equals Failure analysis). \\*Discontinuations and rechallenge with NRTIs are taken into account until Week 48","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Virological Response [Intent To Treat (ITT) - TLOVR, < 50 Copies/ml, Week 48]","description":"Virological response is defined as the number of patients in the ITT population with a plasma viral load \\< 50 HIV RNA copies/ml at Week 48. Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR). In addition, any switch in background nucleoside reverse transcriptase inhibitors (NRTIs) equaled failure\\* (referred to as a Switch Equals Failure analysis). \\*Discontinuations and rechallenge with NRTIs are taken into account until start of Week 48 window","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"Virological Response [Per Protocol (PP), TLOVR - Switch Equals Failure, < 50 Copies/ml, Week 144]","description":"Virological response is defined as the number of patients in the PP population with a plasma viral load \\< 50 HIV RNA copies/ml at Week 144. Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR). In addition, any switch in background nucleoside reverse transcriptase inhibitors (NRTIs) equaled failure\\* (referred to as a Switch Equals Failure analysis). \\*Discontinuations and rechallenge with NRTIs are taken into account until Week 144","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Virological Response [Intent To Treat (ITT), TLOVR - All Switches Included, < 50 Copies/ml, Week 144]","description":"Virological response is defined as the number of patients in the ITT population with a plasma viral load \\< 50 HIV RNA copies/ml at Week 144. Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR). All switches included means that all data even after any changes of treatment were kept. \\*Discontinuations and rechallenge with NRTIs are taken into account until start of Week 144 window.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Virological Response [Per Protocol (PP), TLOVR - Switch Equals Failure, <200 Copies/ml, Week 144]","description":"Virological response is defined as the number of patients in the PP population with a plasma viral load \\< 200 HIV RNA copies/ml at Week 144. Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR). In addition, any switch in background nucleoside reverse transcriptase inhibitors (NRTIs) equaled failure\\* (referred to as a Switch Equals Failure analysis). \\*Discontinuations and rechallenge with NRTIs are taken into account until Week 144","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in CD4+ Cell Count","description":"The mean change in CD4+ cell count from baseline was calculated with a last observation carried forward method; i.e. the last observed value was carried forward, irrespective of the reason for discontinuation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.9","spread":"15.7"},{"groupId":"OG001","value":"-32.9","spread":"14.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.6","spread":"14.7"},{"groupId":"OG001","value":"-20.7","spread":"15.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"14.6"},{"groupId":"OG001","value":"-35.8","spread":"14.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"15.8"},{"groupId":"OG001","value":"-21.1","spread":"14.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":"14.7"},{"groupId":"OG001","value":"-15.1","spread":"16.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"14.9"},{"groupId":"OG001","value":"-2.3","spread":"14.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":"16.1"},{"groupId":"OG001","value":"-12.3","spread":"14.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","spread":"17.2"},{"groupId":"OG001","value":"-3.7","spread":"15.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":"15.9"},{"groupId":"OG001","value":"54.8","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.0","spread":"16.7"},{"groupId":"OG001","value":"87.5","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117.3","spread":"18.3"},{"groupId":"OG001","value":"90.4","spread":"14.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":"15.7"},{"groupId":"OG001","value":"94.9","spread":"15.0"}]}]}]},{"type":"SECONDARY","title":"Resistance Determinations","description":"Number of patients with resistance mutations at any time point when a patient had a viral load \\> 50 copies/mL after randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Total Score","description":"The FAHI is a validated health-related quality of life questionnaire. The questionnaire consist of 44 items and includes 5 functional scales (physical, social, emotional, functional and global well-being and cognitive function). Each item is assessing the impact of HIV on a scale from 0 (not at all) to 5 (very much).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.7"},{"groupId":"OG001","value":"1.7","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.6"},{"groupId":"OG001","value":"3.5","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.7"},{"groupId":"OG001","value":"3.1","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Cognitive Function Subscale","description":"The FAHI cognitive function subscale. Each item is assessing the impact of HIV on cognitive function on a scale from 0 (not at all) to 5 (very much).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Emotional Well-Being Subscale","description":"The FAHI emotional well-being subscale. Each item is assessing the impact of HIV on emotional well-being on a scale from 0 (not at all) to 5 (very much).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.6"},{"groupId":"OG001","value":"1.8","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.5"},{"groupId":"OG001","value":"1.3","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.5"},{"groupId":"OG001","value":"1.7","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Functional and Global Well-Being Subscale","description":"The FAHI functional and global well-being subscale. Each item is assessing the impact of HIV on functional and global well-being on a scale from 0 (not at all) to 5 (very much).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.8"},{"groupId":"OG001","value":"-0.8","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.7"},{"groupId":"OG001","value":"0.4","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.8"},{"groupId":"OG001","value":"0.0","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Physical Well-Being Subscale","description":"The FAHI physical well-being subscale. Each item is assessing the impact of HIV on physical well-being on a scale from 0 (not at all) to 5 (very much).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.5"},{"groupId":"OG001","value":"1.0","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.5"},{"groupId":"OG001","value":"1.4","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.5"},{"groupId":"OG001","value":"1.0","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Social Well-Being Subscale","description":"The FAHI social well-being subscale. Each item is assessing the impact of HIV on physical well-being on a scale from 0 (not at all) to 5 (very much).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.5"},{"groupId":"OG001","value":"-0.2","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.5"},{"groupId":"OG001","value":"0.8","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.5"},{"groupId":"OG001","value":"0.6","spread":"0.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":129},"commonTop":["Diarrhoea","Nasopharyngitis","Hypercholesterolaemia","Bronchitis","Headache"]}}}